KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Inventory (2018 - 2025)

Castle Biosciences' Inventory history spans 7 years, with the latest figure at $10.3 million for Q4 2025.

  • For Q4 2025, Inventory rose 26.05% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $10.3 million, up 26.05%, while the annual FY2025 figure was $10.3 million, 26.05% up from the prior year.
  • Inventory for Q4 2025 was $10.3 million at Castle Biosciences, up from $8.6 million in the prior quarter.
  • Across five years, Inventory topped out at $10.3 million in Q4 2025 and bottomed at $2.0 million in Q4 2021.
  • The 5-year median for Inventory is $5.9 million (2023), against an average of $5.6 million.
  • The largest annual shift saw Inventory soared 99.55% in 2023 before it dropped 10.41% in 2025.
  • A 5-year view of Inventory shows it stood at $2.0 million in 2021, then skyrocketed by 96.93% to $4.0 million in 2022, then skyrocketed by 99.55% to $7.9 million in 2023, then rose by 2.43% to $8.1 million in 2024, then increased by 26.05% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Inventory are $10.3 million (Q4 2025), $8.6 million (Q3 2025), and $8.4 million (Q2 2025).